

**INVESTOR PRESENTATION
FY2023 RESULTS & US FDA 510(k) SUBMISSION FOR GASTROINTESTINAL
PARASITE DETECTION KIT**

Genetic Signatures [ASX: GSS], a global molecular diagnostics company, is pleased to announce that it will be holding an online investor presentation at 11:00 am on Monday 4th September. This presentation can be viewed live via Zoom. To register at no cost, please copy and paste the following link into your internet browser.

Investor Zoom Webinar 11:00am AEST Monday 4 September

You are invited to register using this link:

https://us06web.zoom.us/webinar/register/WN_esyXtX4tS1WZ8gTZTIXGYA

Participants may submit questions during registration or during the session

A copy of the presentation will be emailed to all registrants after the presentation.

For further information about Genetic Signatures, visit our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

**Managing Director and
Chief Executive Officer**

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann

**Chief Financial and Operating Officer
and Company Secretary**

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures' proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.